KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Gains from Investment Securities (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Gains from Investment Securities data on record, last reported at -$1.4 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 80.28% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached -$400000.0, up 93.85%, while the annual FY2025 figure was -$400000.0, 93.85% up from the prior year.
  • Gains from Investment Securities reached -$1.4 million in Q4 2025 per EBS's latest filing, up from -$8.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $18.6 million in Q2 2025 and bottomed at -$10.8 million in Q3 2022.
  • Average Gains from Investment Securities over 5 years is -$810526.3, with a median of $100000.0 recorded in 2024.
  • The widest YoY moves for Gains from Investment Securities: up 18500.0% in 2025, down 2000.0% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at -$6.1 million in 2021, then soared by 267.21% to $10.2 million in 2022, then plummeted by 94.12% to $600000.0 in 2023, then tumbled by 1283.33% to -$7.1 million in 2024, then skyrocketed by 80.28% to -$1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$1.4 million in Q4 2025, -$8.1 million in Q3 2025, and $18.6 million in Q2 2025.